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A liposomal delivery system that coordinates the release of irinotecan and floxuridine in vivo has been developed. The encapsulation of
floxuridine was achieved through passive entrapment while irinotecan was actively loaded using a novel copper gluconate/triethanolamine based
procedure. Coordinating the release rates of both drugs was achieved by altering the cholesterol content of distearoylphosphatidylcholine (DSPC)/
distearoylphosphatidylglycerol (DSPG) based formulations. The liposomal retention of floxuridine in plasma after intravenous injection was
dramatically improved by decreasing the cholesterol content of the formulation below 20 mol%. In the case of irinotecan, the opposite trend was
observed where increasing cholesterol content enhanced drug retention. Liposomes composed of DSPC/DSPG/Chol (7:2:1, mole ratio) containing
co-encapsulated irinotecan and floxuridine at a 1:1 molar ratio exhibited matched leakage rates for the two agents so that the 1:1 ratio was
maintained after intravenous administration to mice. The encapsulation of irinotecan was optimal when copper gluconate/triethanolamine (pH 7.4)
was used as the intraliposomal buffer. The efficiency of irinotecan loading was approximately 80% with a starting drug to lipid molar ratio of
0.1/1. Leakage of floxuridine from the liposomes during irinotecan loading at 50 °C complicated the ability to readily achieve the target 1:1
irinotecan/floxuridine ratio inside the formulation. As a result, a procedure for the simultaneous encapsulation of irinotecan and floxuridine was
developed. This co-encapsulation method has the advantage over sequential loading in that extrusion can be performed in the absence of
chemotherapeutic agents and the drug/drug ratios in the final formulation can be more precisely controlled.
© 2006 Elsevier B.V. All rights reserved.Keywords: Liposomes; Irinotecan; Floxuridine; Coordinated release; Metal loading1. Introduction
Liposomes have been used extensively to improve the
therapeutic index of a variety of drugs by ameliorating toxicity
and/or increasing the therapeutic potency of the encapsulated
agent [1,2]. This is perhaps best exemplified in the delivery of
anticancer drugs where it has been well documented both
preclinically and clinically that small (approximately 100 nm)
liposomes reduce exposure of entrapped drugs to susceptible
healthy tissues while preferentially accumulating in sites of
tumor growth due to enhanced permeability and retention (EPR)⁎ Corresponding author. Tel.: +1 604 675 2105; fax: +1 604 708 5883.
E-mail address: ptardi@celatorpharma.com (P.G. Tardi).
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.11.014effects associated with solid tumors [3–6]. This in turn has often
resulted in improvements of the overall therapeutic activity of
the drug and has led to the regulatory approval of several
liposome-based anticancer products [7,8]. Interestingly, very
little work has been undertaken to deliver drug combinations in
liposomes. This is likely the result of difficulties associated with
the efficient and stable encapsulation of two chemotherapeutics
inside a single liposome as well as challenges in controlling the
release of chemically disparate drugs with one liposome
composition.
Our interest in developing liposome formulations containing
co-encapsulated anticancer drug combinations stems from the
fact that virtually all curative cancer treatment regimens utilize
drug combinations. We hypothesized that enhanced antitumor
activity may be achieved by simultaneously delivering and
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since tumor cells would be less able to develop compensatory
resistance mechanisms compared to single or sequentially
administered agents. This approach became of even greater
importance when we recently observed that the antitumor
activity of drug combinations can be dramatically dependent on
the molecular ratio of the combined drugs [9]. Specifically,
some ratios of a drug combination can be synergistic whereas
other ratios of the same drugs can be additive or even
antagonistic [10]. This highlighted the need to control drug
ratios being exposed to tumor cells after systemic administration
since the uncontrolled and dissimilar pharmacokinetics of
individual drugs utilized in conventional drug “cocktails” no
doubt results in exposure to sub-optimal drug ratios with a
concomitant loss in therapeutic activity. Further, although an
increasing number of individual liposomal anticancer drugs are
being developed, the pharmacokinetics of currently available
formulations vary greatly which would hinder attempts to
coordinate the exposure of different drugs using existing lipo-
some formulations [11,12]. In addition, combining multiple
liposome-based anticancer drugs poses potential difficulties due
to high lipid doses which have been shown in humans to lead to
infusion-related adverse events [13,14].
In view of the above considerations, we undertook a series of
studies aimed at developing single liposome formulations that
are able to stably co-encapsulate drug combinations and
coordinate the release of the two agents after intravenous (i.v.)
injection. In this report we describe the co-encapsulation of
irinotecan and floxuridine. This drug combination was selected
based on the fact that irinotecan and fluoropyrimidine (typically
5-fluorouracil, 5-FU) combination treatment is standard of care
for metastatic colorectal cancer. The focus on floxuridine rather
than 5-FU was based on the superior encapsulation and
retention properties of floxuridine compared to 5-FU [15] and
the fact that trials conducted in the 1960s established the clinical
equivalency of these two fluoropyrimidines [16,17]. We have
shown in previous studies that a 1:1 molar ratio of these drugs
optimizes drug synergy in a panel of gastrointestinal tumor lines
[9]. We describe here the identification of liposome encapsula-
tion techniques and lipid compositions that result in stable drug
entrapment and drug release rates that maintain irinotecan and
floxuridine at a 1:1 molar ratio after i.v. administration.
2. Materials and methods
2.1. Lipids, drugs and chemicals
Distearoylphosphatidylglycerol (DSPG), distearoylphosphatidylcholine
(DSPC) and cholesterol were obtained from Avanti Polar Lipids (Alabaster,
AL, USA). Irinotecan hydrochloride trihydrate (Camptosar) is a product of
Pharmacia and Upjohn Company (Kalamazoo, MI, USA) and was obtained
from the pharmacy of the British Columbia Cancer Agency. It was also obtained
as a dry powder from ScinoPharm Taiwan, Ltd. (Tainan, Taiwan). Floxuridine
was obtained from the Zhejiang Hisun Pharmaceutical Company (Taizhou City,
China). Radiolabelled [3H]floxuridine was obtained from Moravek Biochem-
icals (Brea, CA, USA). Cholesterol hexadecyl ether (CHE) radiolabelled with
[3H] or [14C] was obtained from NEN Life Science Products (Oakville, ON,
Canada). All other chemicals were purchased from Sigma Chemical Company
(St. Louis, MO, USA).2.2. Preparation of liposomes
Based on the appropriate molar composition, DSPC and DSPG were
dissolved in chloroform/methanol/water (5/1/.1) at 50 mg/ml and combined with
cholesterol dissolved in chloroform. Where appropriate, cholesteryl hexadecyl
ether [14C]CHE or [3H]CHE was added as a non-exchangeable, non-
metabolizable lipid marker [18]. The solvent was removed under a stream of
nitrogen gas and the lipid films placed under high vacuum overnight. Typically,
the lipid films were rehydrated at 70 °C with 100 mM copper gluconate,
220 mM triethanolamine (TEA), pH 7.4. The pH of the copper gluconate
solution was adjusted by varying the TEA content and not through the addition
of sodium hydroxide. In experiments involving the sequential loading of
floxuridine and irinotecan, the floxuridine was passively trapped in the
liposomes by adding 122 mM floxuridine plus [3H]floxuridine as a tracer to
the copper gluconate buffer. The newly formed multilamellar vesicles (MLVs)
were passed 10 times through an extruding apparatus (Northern Lipids)
containing two stacked 100 nm polycarbonate filters. The mean diameter and
size distribution of each liposome preparation, analyzed by a NICOMP Model
270 Submicron particle sizer (Pacific Scientific, Santa Barbara, CA, USA)
operating at 632.8 nm, was typically 110±20 nm. Following extrusion the
external liposomal buffer was exchanged for 300 mM sucrose, 20 mM HEPES,
30 mM EDTA, pH 7.4 (SHE) using tangential flow chromatography.
2.3. Time course of irinotecan encapsulation
The following conditions were used to examine irinotecan encapsulation
into liposomes containing various metal salts, copper gluconate at different pH
and irinotecan to lipid ratios. Irinotecan (Camptosar) and liposomes were heated
separately at 50 °C for 1 min and then combined at t=0 by adding the lipid to the
drug while vortexing. The final lipid concentration was diluted to 30 mM using
SHE buffer. Aliquots of 100 μl were removed at various time points and applied
to 1 ml Sephadex G-50 spin columns. The columns were prepared by adding
glass wool to a 1 ml syringe and Sephadex G-50 beads hydrated in HEPES
buffered saline (HBS; 20 mM HEPES, 150 mM NaCl, pH 7.4). The columns
were packed by spinning at 500×g for 2 min. Following addition of the sample
to the column, the liposome fraction was collected in the void volume by
centrifuging at 650×g for 1 min. Aliquots of the spin column eluant and the pre-
column solution were taken and analyzed by liquid scintillation counting to
determine the lipid concentration at each time point. The irinotecan
concentration in each liposomal fraction was determined using a UV based
assay. Briefly, a 100 μl aliquot of each liposomal sample (or smaller volume
adjusted to 100 μl with distilled water) was solubilized in 100 μl of 10% Triton
X-100 plus 800 μl of 50 mM citrate/trisodium citrate, 15 mM EDTA, pH 5.5 and
heated in boiling water until the cloud point was reached. The samples were
cooled to room temperature and the absorbance at 370 nm measured and
compared to a standard curve. For mouse studies utilizing irinotecan containing
formulations, the unencapsulated irinotecan and EDTA was removed by
replacing the external buffer with SH buffer (300 mM sucrose, 20 mM HEPES,
pH 7.4) using tangential flow chromatography.
2.4. Simultaneous encapsulation of irinotecan and floxuridine
A lipid film composed of DSPC/DSPG/Chol (7:2:1, mol/mol/mol) was
prepared as previously described in Section 2.2 containing [14C]CHE as the lipid
marker. The film was hydrated with 100 mM copper gluconate, 220 mM TEA,
pH 7.4 at 70 °C and the resulting MLVs were extruded at 70 °C through two
stacked 100 nm filters for a total of ten passes. The liposomes were subsequently
exchanged for SHE using tangential flow chromatography and concentrated to
60 mg/ml. To prepare a drug solution containing floxuridine and irinotecan, 3H-
floxuridine was first added to a test tube and dried under a stream of nitrogen.
Subsequently, floxuridine and irinotecan were added to the same tube as a
powder and hydrated with SHE buffer. The pH of the drug solution was adjusted
to 7.4 with NaOH. The amount of irinotecan in the loading solution was based
on a 0.12 drug to lipid molar ratio. The final floxuridine concentration was
adjusted so that a concentration of 122 mM would be achieved after its addition
to the liposome solution. The drug solution and the liposomes were incubated
separately at 50 °C for approximately 5 min to equilibrate the temperature. The
Fig. 1. Irinotecan encapsulation into DSPC/Chol (55:45, mol%) liposomes using
various metal salts. Liposomes radiolabelled with [3H]CHE were extruded in the
presence of various unbuffered metal salt solutions and subsequently exchanged
into SHE buffer (pH 7.4). The liposomes were incubated at 50 °C in the presence
of irinotecan at a 0.1/1 molar drug to lipid ratio. At various time points aliquots
were removed and assayed for drug encapsulation as outlined in Section 2.3. The
following metal solutions, CuSO4 (▾); ZnSO4 (▿); MnSO4 (▪); CoSO4 (●)
and NiSO4 (○) were all prepared at a concentration of 300 mM and were not pH
adjusted (representative data shown).
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time points and applied to a Sephadex G-50 spin column as previously
described. The drug to lipid ratio for floxuridine, from the eluted column sample,
was determined using dual label liquid scintillation counting. The irinotecan
concentration was determined by measuring the irinotecan absorbance at
370 nm as previously described.
2.5. Mice
Female Balb/c mice (6–8 weeks), 20–22 g breeders were purchased from
Charles River Laboratories (St. Constant, PQ, Canada) and bred in house. Mice
were housed in microisolator cages and given free access to water and food. The
animals were maintained according to the procedures established at the BC
Cancer Agency Joint Animal Facility. All animal studies were approved by the
University of British Columbia Animal Care Committee in accordance with the
guidelines established by the Canadian Council of Animal Care.
2.6. Plasma elimination of liposomes
To determine the retention of irinotecan and floxuridine in various liposomal
formulations in vivo, plasma elimination studies were performed. Radiolabelled
liposomes containing floxuridine and/or irinotecan were administered at the
appropriate concentration intravenously into the lateral tail vein of mice. At 1, 4
and 24 h after administration, mice were asphyxiated with CO2 and the blood
collected by cardiac puncture and placed into EDTA coated microtainer tubes.
The blood was centrifuged at 900×g for 10 min at 4 °C to isolate the plasma
fraction. Liposomes and floxuridine concentrations were determined by liquid
scintillation counting while irinotecan concentrations were determined by
HPLC.
2.7. Irinotecan quantitation using HPLC
To determine the T=0 irinotecan concentration in the liposome sample prior
to injection, the liposomes were diluted 1:100 in saline. Subsequently, a 100 μL
aliquot of the diluted liposome sample was mixed with internal standard
(camptothecin), followed by adding 600 μL acidified methanol (pH 2.0). For
determination of irinotecan HCl in plasma, 10 μL (1-h and 4-h time points) or
20 μL (24-h time points) mouse plasma was mixed with 10 μL internal standard
(camptothecin) followed by adding 600 μL acidified methanol (pH 2.0).
Samples were then vortexed vigorously and stored in −70 °C freezer for 1 h.
After cooling, the samples were centrifuged for 10 min at 1500×g and the
supernatant was analyzed for irinotecan HCl using HPLC. The chromatographic
system consisted of a Waters Alliance 2695 system and 2475 fluorescence
detector. Waters Symmetry reverse phase C18 column (4.6×250 mm, 5μ)
protected by a Symmetry Sentry guard column (3.9×20 mm, 5μ) was used for
chromatographic separation. The analytical column was maintained at a
temperature of 30 °C. The mobile phase was composed of acetonitrile
−75 mM ammonium acetate containing 7.5 mM tetrabutylammonium bromide
(24:76, v/v), with pH adjusted to 6.4 using glacial acetic acid. The mobile phase
was delivered isocratically at a flow rate of 1.5 mL/min. Column elute was
monitored fluorimetrically at excitation wavelength of 362 nm and emission
wavelength of 425 nm. Detection and integration of chromatographic peaks was
performed by Waters Empower software. Irinotecan HCl concentration was
calculated using a calibration curve (linear range 2–100 μg/mL).
3. Results
3.1. Irinotecan encapsulation into transition metal containing
liposomes
Based on the structure of irinotecan and the documented
ability of transition metals to interact with drugs [19], we
hypothesized that the presence of a free hydroxyl on the E-ring
adjacent to the lactone group could be a candidate for the
formation of a coordination complex with metal ions [20,21],thus enabling active loading of the irinotecan into preformed
liposomes containing a metal salt solution. To determine if
irinotecan could be encapsulated into liposomes using transition
metals, DSPC/Chol (55:45 mol/mol) liposomes were prepared
containing 300 mM sulfate salts of manganese, zinc, copper,
nickel or cobalt. The liposomes were incubated with irinotecan
at 50 °C using a drug to lipid ratio of 0.1:1 (mol/mol) for 1 h.
This temperature was selected based on the fact that
temperatures ≤40 °C provided very slow irinotecan encapsula-
tion rates (data not shown). At various time points, aliquots
were removed and the encapsulated drug to lipid ratio was
determined (Fig. 1). Less than 10% encapsulation was observed
under these conditions for all metals except zinc and copper
which rapidly accumulated irinotecan. Zinc encapsulation was
less efficient than copper with a maximum irinotecan to lipid
ratio of 0.075:1 (mol/mol) and showed a gradual decrease in
trapped irinotecan over the 60-min time course. Irinotecan
encapsulation into copper containing liposomes was very effec-
tive with >95% encapsulation efficiency at all time points
tested. It should be noted that although evidence of transition
metal–fluoropyrimidine interactions have been reported [22],
attempts to actively encapsulate floxuridine into metal contain-
ing liposomes in a manner similar to irinotecan were unsuccess-
ful (data not shown).
Numerous copper salts (chloride, sulfate, nitrate, gluconate
and tartrate) are commercially available, however, only the
sulfate and gluconate forms were found to be sufficiently
soluble and stable to promote efficient irinotecan encapsula-
tion described here. When dissolved in water, both the sulfate
and gluconate forms of copper are acidic with a pH of
approximately 4. Since it was desirable to have an internal
liposomal pH near neutrality, the copper solutions were
adjusted to pH 7.4. When copper sulfate was pH adjusted
with sodium hydroxide, however, a significant copper oxide
Fig. 2. The influence of liposome composition on the retention of floxuridine in
vivo. Liposomes composed of either DSPC/DSPG (8:2 molar ratio, ●) or
DSPC/Chol (55: 45 molar ratio, ○) were radiolabelled with [14C]CHE were
extruded in the presence of a 100 mM solution of [3H]floxuridine dissolved in
HBS (pH 7.4). The unencapsulated floxuridine was exchanged for saline using
tangential flow chromatography. The liposomes were injected into the tail vein
of female Balb/c mice at a floxuridine dose of 5 mg/kg. Blood was collected
via cardiac puncture at 1, 4 and 24 h after injection (3 mice per time point). Lipid
and floxuridine recovery was determined by liquid scintillation counting.
Fig. 3. The effect of pH on irinotecan encapsulation. Liposomes composed of
DSPC/DSPG (80:20 molar ratio) were radiolabelled with [3H]CHE and extruded
in the presence of 100 mM copper gluconate that was pH adjusted with TEA to
pH 7.5 (▿); pH 7 (▾); pH 6.5 (○) or pH 6 (●). The external liposomal solution
was replaced with 150 mM NaCl, 10 mM HEPES and 10 mM MES which was
pH adjusted to match the internal liposomal pH. Irinotecan was incubated with
the liposomes at 50 °C and at various times aliquots were removed and passed
through a spin column to determine the extent of irinotecan encapsulation. The
irinotecan to lipid ratio was determined as described previously in Section 2.3
(representative data shown).
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buffer triethanolamine (TEA) was found to be the most com-
patible buffer for both copper sulfate and copper gluconate pH
adjustment. When pH 7.4 solutions of copper gluconate and
copper sulfate were compared for their ability to encapsulate
irinotecan, the copper gluconate solution was found to be superior
in total capacity, percent encapsulation and drug retention (data
not shown). As a result, all subsequent formulation studies
focused on copper gluconate buffered with TEA. It should be
noted that stable liposome formulations containing gluconate
salts of the other transition metals buffered to physiological pH
could not be prepared due to instability of the salt solution which
lead to significant precipitation (data not shown).
3.2. Floxuridine encapsulation and retention in liposomes
Since floxuridine could not be actively loaded into lipo-
somes via metal complexation, the drug was passively encap-
sulated into liposomes by hydrating lipid films in the presence
of floxuridine solutions. A previous study reported that the
trapping efficiency of floxuridine can be increased when
trapped in negatively charged liposomes [15]. Also, recent
studies have shown that cholesterol-free liposomes can enhance
the retention properties of certain drugs [23]. Taken together,
this information led us to investigate the in vivo drug retention
properties of cholesterol-free, negatively charged liposomes
composed of DSPC/DSPG (80:20, mol/mol) compared to
DSPC/Chol (55:45, mol/mol) formulations. As shown in Fig. 2,
the retention of floxuridine (reflected by maintenance of the
encapsulated drug to lipid ratio) inside liposomes after i.v.
injection to mice was found to be superior in the cholesterol free
formulation. The half life for the release of floxuridine from the
liposomes increased from approximately 1 h for DSPC/Chol
(55:45, mol/mol) liposomes to approximately 16 h for theDSPC/DSPG (80:20, mol/mol) formulation. Based on the
superior floxuridine retention properties and circulation life-
times, the DSPC/DSPG formulation was studied as a potential
delivery system for the drug combination of irinotecan and
floxuridine.
3.3. Co-formulation of irinotecan and floxuridine
Initial studies on the co-formulation of irinotecan and
floxuridine focused on the hydration of lipid films with
solutions of copper gluconate/TEA that contained floxuridine.
However, irinotecan encapsulation was not affected by the
presence or absence of floxuridine within the liposomes. As a
result, the optimization of irinotecan loading was determined in
the absence of entrapped floxuridine. The liposomes hydrated
from lipid films were extruded and the unencapsulated copper
was removed by tangential flow dialysis. The conditions that
were found to impact the subsequent encapsulation of irinotecan
to the greatest degree were pH and temperature. To determine
the optimal pH for irinotecan loading, liposomes were prepared
with matching internal and external buffer pH. The time course
for irinotecan loading into liposomes at 50 °C is presented in
Fig. 3. Maximum irinotecan encapsulation leading to a final
drug to lipid ratio of approximately 0.8:1 (mol/mol) was
achieved with buffers at pH 7.0 and 7.5. This reflected an
encapsulation efficiency of 80% based on the starting irinotecan
to lipid ratio of 0.1:1 (mol/mol). The rate of irinotecan
accumulation inside the copper containing liposomes was
most rapid at pH 7.5 where uptake levels were 85% of
maximum within 5 min. Decreasing the pH to 6.5 or 6.0 resulted
in decreased rates of irinotecan accumulation and liposome
uptake levels after incubating for 60 min were 0.061 and
0.039 μmole drug/μmol lipid, respectively. Due to the similar
Fig. 4. The in vivo retention of floxuridine and irinotecan coformulated in
DSPC/DSPG (80:20 molar ratio) liposomes. Liposomes were radiolabelled with
[14C]CHE and extruded in the presence of 100 mM copper gluconate/TEA pH
7.4 containing [3H] labelled floxuridine. The external buffer was exchanged for
SHE (pH 7.4) and loaded with irinotecan at a drug to lipid molar ratio of 0.1/1.
The unencapsulated irinotecan and EDTAwas removed by exchanging into SH
buffer using tangential flow chromatography. Mice were injected via the tail
vein at a lipid dose of 200 μmol/kg (16 μmol/kg of irinotecan and floxuridine).
Blood was recovered at 1, 4 and 24 h after injection and centrifuged to isolate
plasma (3 mice per time point). Lipid and floxuridine (●) levels were
determined by liquid scintillation counting while irinotecan (○) concentrations
were determined by HPLC analysis.
Fig. 5. The in vivo retention of floxuridine and irinotecan coformulated in
various liposomal formulations. Liposomes composed of DSPC/Chol/DSPG
(65:15:20 molar ratio);▿, DSPC/Chol/DSPG (70:10:20 molar ratio);▾, DSPC/
Chol/DSPG (75:5:20 molar ratio); ○, and DSPC/DSPG (80:20 molar ratio); ●
were radiolabelled with [14C]CHE and coformulated with irinotecan and
floxuridine as previously described. Samples were injected into the tail vein of
mice at a lipid dose of 370 μmoles/kg (37 μmoles/kg irinotecan and floxuridine).
At 1, 4 and 24 h after injection blood was collected and assayed for lipid,
irinotecan and floxuridine levels (3 mice per time point). Changes to irinotecan
to lipid levels with time are monitored in the upper panel while the middle panel
plots the floxuridine to lipid levels from the same formulation. The lower panel
charts changes in the drug: drug molar ratio in the various liposomal
formulations over time.
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pH of 7.4 was chosen for all subsequent studies.
Liposomes composed of DSPC/DSPG (80:20, mol/mol),
containing both floxuridine and irinotecan at a molar drug ratio
of 1:1 (drug to lipid molar ratios of approximately 0.08:1), were
administered i.v. into mice to determine if this formulation
could coordinate drug release after injection. The drug to lipid
ratio for both drugs was monitored in the plasma over 24 h as an
indicator of drug release from the liposomes in the circulation.
As shown in Fig. 4, the retention of floxuridine in this
cholesterol-free formulation was far greater than that observed
for irinotecan. The floxuridine drug to lipid ratio decreased
linearly over time with a half life of approximately 14 h and
22% of the original drug to lipid ratio remained after 24 h. In
contrast, the retention of irinotecan was poor with greater than
60% drug leakage within the first hour after injection and the
plasma irinotecan to lipid ratio at 24 h was only 5% of the
starting drug to lipid ratio. This large difference in drug release
rates lead to circulating irinotecan/floxuridine ratios that rapidly
deviated from the desired 1:1 ratio. It should be noted that the
rates of irinotecan and floxuridine release when co-formulated
inside the same liposome were similar to those obtained for each
respective drug encapsulated individually inside the liposomes
(data not shown).
In order to better coordinate the release of irinotecan and
floxuridine co-formulated inside 100 nm liposomes, an iterative
variation of lipid composition was performed. Since cholesterol
content was shown to have a dramatic impact on the retention of
floxuridine (Fig. 2), we reasoned that it may also play a role in
the retention of irinotecan. Various liposome formulations
containing cholesterol at levels ranging from 0 to 15% were
tested for drug retention in vivo. At 1, 4 and 24 h after injection,blood was collected and the plasma was analyzed for irinotecan,
floxuridine and lipid levels. Irinotecan to lipid ratios were found
to be significantly affected by cholesterol content (Fig. 5, top
panel). In the formulations containing 0 or 5% cholesterol, rapid
leakage of irinotecan is observed. One hour after injection of
these formulations, the circulating liposomes retained only 38%
Fig. 6. The extent of irinotecan encapsulation at various starting drug to lipid
ratios. Liposomes composed of DSPC/Chol/DSPG (70:10:20 molar ratio) were
radiolabelled with [3H]CHE and incubated with irinotecan at drug to lipid molar
ratios of 0.1:1 (●), 0.2:1 (○) and 0.3 :1 (▾). The reaction was carried out at
50 °C for various times and assayed for drug encapsulation as previously
described (representative data shown).
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When the cholesterol content was increased to 10 and 15 mol%,
we observed 84 and 97% of initial irinotecan to lipid ratios in
the plasma after 1 h. The small increase in cholesterol content
from 5 to 10 mol% increased the irinotecan half life by
approximately 6.5-fold from 1.5 h to 10 h. This large depen-
dency of irinotecan retention in vivo on cholesterol content was
not observed at liposome cholesterol levels above 10 mol%.
The sensitivity of irinotecan retention in the 10 mol%
cholesterol range was subsequently investigated with formula-
tions containing 7.5, 10 and 12.5 mol% cholesterol. Analysis of
irinotecan release rates over 24 h found no significant
differences between these three formulations (data not
shown). As a result it appears that irinotecan retention is not
correlated with cholesterol content in a linear fashion but
requires a minimum threshold level. In addition, it should be
noted that irinotecan can exist in an open ring carboxylate or
closed ring lactone form. Only the lactone form of the drug is
biologically active and was found to be the predominant form
(>90%) in all the liposomal formulations tested.
The release of floxuridine from DSPC/DSPG-based lipo-
somes as a function of cholesterol content was monitored and
the results are presented in Fig. 5 (middle panel). Unlike
irinotecan, floxuridine retention was not significantly influ-
enced by cholesterol content between 0 and 15 mol%. The drug
to lipid half life for floxuridine ranged from a high of
approximately 13 h in the cholesterol free formulation to a
low of approximately 11 h in the 15 mol% formulation. This
was somewhat surprising since the results shown in Fig. 2
suggest that floxuridine leakage is dramatically enhanced in the
presence of 45 mol% cholesterol. The fact that little difference
was observed between 0 and 15 mol% cholesterol suggests that,
similar to irinotecan leakage, there appears to be a threshold
amount of cholesterol that is required before large changes in
drug release are observed. When the encapsulated irinotecan to
floxuridine molar ratio was plotted (Fig. 5, lower panel) for the
0 and 5 mol% formulations, the starting drug to drug molar ratio
was observed to drop from 1:1 to 1:2 within 1 h. The initial drop
in the molar drug ratio is the result of rapid leakage of irinotecan
from these formulations. Following the initial drop at 1 h, the
molar drug ratio is maintained out to 24 h. In the formulation
containing 15 mol% cholesterol, the opposite trend was
observed where the drug to drug ratio increases as a result of
enhanced irinotecan retention relative to floxuridine. The
synergistic 1:1 molar drug ratio was optimally maintained in
the formulation containing 10 mol% cholesterol for which the
release rates of both agents was matched.
3.4. Optimization of drug encapsulation
The studies described thus far have demonstrated that
irinotecan and floxuridine can be stably co-encapsulated at a
1:1 molar ratio inside DSPC/DSPG/Chol (70:20:10, mol/mol)
liposomes containing copper gluconate/TEA pH 7.4 and that
these liposomes coordinate the release of the two drugs, thereby
maintaining the irinotecan/floxuridine ratio for extended times
after i.v. administration. In an attempt to increase the liposomaldrug capacity, copper gluconate/TEA pH 7.4 containing
liposomes were incubated at elevated starting irinotecan to
lipid ratios to determine the maximum amount of drug that
could be loaded into these formulations. Irinotecan encapsula-
tion was not affected by the presence or absence of floxuridine
within the liposomes, therefore irinotecan loading was deter-
mined in the absence of entrapped drug. At a starting drug to
lipid ratio of 0.1:1, approximately 80% drug encapsulation is
observed (Fig. 6). A similar encapsulation efficiency was
observed at a starting irinotecan to lipid molar ratio of 0.2:1
where the final encapsulated drug to lipid ratio was approxi-
mately 0.15:1. However, when the starting irinotecan to lipid
ratio was elevated to 0.3:1 the encapsulated irinotecan to lipid
ratio increased only to 0.18:1, reflecting a decrease in
encapsulation efficiency to approximately 60%. As a result,
incubating the liposomes with irinotecan at a 0.2:1 ratio
provided the highest drug to lipid ratio in the final formulation
(0.14–0.15/1) without significantly decreasing the irinotecan
loading efficiency.
Floxuridine levels were also increased in the liposome
formulations in order to compensate for the increase in
irinotecan to lipid ratio and maintain the 1:1 molar drug ratio
inside the liposomes. This was achieved by extruding the
liposomes in the presence of elevated floxuridine concentra-
tions. However, floxuridine leakage during irinotecan encapsu-
lation at 50 °C when the higher drug to lipid ratios were utilized
caused significant difficulty in controlling final irinotecan to
floxuridine ratios in the liposomes. This effect is reflected in
Fig. 7 which presents the encapsulated floxuridine to lipid ratio
over time for liposomes incubated at temperatures ranging from
40 °C to 60 °C. Floxuridine release from DSPC/DSPG/Chol
(70:20:10, mol/mol) liposomes at 40 °C and 45 °C was <10%
over 20 min, however under these conditions, irinotecan
encapsulation was <50% (data not shown). In contrast, >90%
floxuridine release was observed within 5 min when the
liposomes were incubated at ≥55 °C. The rapid drug release at
this temperature occurred as a result of the liposomal membrane
Fig. 8. The drug to lipid ratio of irinotecan and floxuridine during simultaneous
drug loading. Liposomes composed of DSPC/Chol/DSPG (70:10:20 molar
ratio) were radiolabelled with [14C]CHE and incubated at 50 °C with [3H]
floxuridine and irinotecan as outlined in Section 2.4. At various time points
aliquots were removed and passed through a Sephadex G-50 spin column to
determine the irinotecan to lipid ratio (●) and the floxuridine to lipid ratio (○)
(representative data shown).
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phase transition temperature (Tm) of 54.5 °C as measured using
differential scanning calorimetry (data not shown). By decreas-
ing the loading temperature to 50 °C, approximately 10% drug
leakage was observed after 10 min, at which time irinotecan
loading achieved maximum levels (see Fig. 3).
3.5. Simultaneous drug loading
In view of the difficulties associated with reproducibly
achieving target irinotecan/floxuridine ratios inside DSPC/
DSPG/Chol (70:20:10, mol/mol) liposomes with descending
floxuridine entrapment due to leakage during irinotecan
encapsulation, we examined alternative entrapment procedures
whereby the two drugs could be simultaneously loaded
subsequent to liposome formation and extrusion. We reasoned
that if floxuridine could leak from liposomes when incubated at
50 °C, it should also be possible for the drug to load into
preformed liposomes by following its concentration gradient
and equilibrating across the liposome bilayer during irinotecan
encapsulation. This approach relied on the ability of floxuridine
and irinotecan to permeate the membrane under conditions
where copper remained inside the liposomes. Liposomes were
extruded in the presence of copper gluconate/TEA (pH 7.4) in
the absence of floxuridine and then buffer exchanged to remove
unencapsulated copper. Just prior to liposome loading, a single
drug solution containing irinotecan and floxuridine was
prepared. As shown in Fig. 8, floxuridine passively accumu-
lated into liposomes simultaneously with irinotecan active
encapsulation without compromising the integrity of irinotecan
loading. The similar kinetics of liposome accumulation for
floxuridine and irinotecan facilitated the ability to precisely
control the drug/drug ratios in the final formulation and reliablyFig. 7. The extent of floxuridine leakage fromDSPC/Chol/DSPG (70:10:20 molar
ratio) liposomes at various temperatures. Liposomes labelled with [14C]CHE
were extruded in the presence of 122 mM [3H]floxuridine in HBS pH 7.4 and
subsequently buffer exchanged to remove unencapsulated drug. To monitor
the leakage rates of floxuridine from the formulation at a range of tempera-
tures, the liposomes were incubated at 40 °C (●), 45 °C (○), 50 °C (▾),
55 °C (▿) and 60 °C (▪) for 2 h. At various time points, aliquots were
removed and passed though a Sephadex G-50 spin column and assayed for
lipid and floxuridine content using liquid scintillation counting (representative
data shown).achieve the target 1:1 molar ratio. It should be noted that the
pharmacokinetics and drug release properties of this formula-
tion did not differ from those observed with liposome
formulations in which floxuridine and irinotecan were sequen-
tially loaded (see Fig. 5).
4. Discussion
The use of drug combinations has been standard of care in
the treatment of cancer for many years. Given this and the
expanded use of liposomal delivery vehicles for cancer
chemotherapy, it is somewhat surprising that very little research
has focused on the development of liposomal drug combina-
tions, either in separate liposomes or co-encapsulated in the
same liposome. This may be related to expectations that the
activity of liposomal drug combinations would simply be the
sum of the individual liposomal drug components. In fact, the
limited examples where liposomal drug combinations have
been investigated resulted in therapeutic activity that was less
than predicted for additivity [24,25]. Such adverse outcomes
could have resulted from unfavorable pharmacological interac-
tions such as restricted delivery of encapsulated drugs to tumor
sites, counteractive drug activities or altered drug release rates.
We have recently identified a new and potentially important
application for liposome delivery of drug combinations. This
application arose from in vitro observations in cytotoxicity
assays where the degree of drug synergy or antagonism has
been shown to be dependent on the ratio of drugs in the
combination [9]. The implications of this observation are that
unless drug combinations are maintained in a synergistic range
after administration in vivo, therapeutic activity will be
compromised. Clearly, such control of systemic drug ratios
after injection of unencapsulated drug cocktails is difficult, if
not impossible, to achieve. Our approach to this problem is
therefore to: (1) identify the optimum drug/drug ratio in a range
of in vitro tumor cell lines, (2) design liposomes that can co-
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drug/drug ratio in the synergistic range after administration so it
can be exposed to tumor cells in vivo. One of the first drug
combinations we applied this approach to was irinotecan and
floxuridine, which are commonly used in the treatment of
colorectal cancer [26–28]. This drug combination exhibited
drug ratio-dependent synergy when examined in vitro where a
1:1 molar ratio was shown to be optimal over a broad range of
tumor cell lines [9,29]. Consequently, we focused efforts to
generate liposome formulations that could both encapsulate and
maintain this drug combination at a 1:1 ratio.
In practical terms, the most challenging hurdle to achieving
coordinated pharmacokinetics of drug combinations co-encap-
sulated in liposomes is the development of a single formulation
that can simultaneously, yet independently control the release of
two drugs that exhibit very differing physico-chemical proper-
ties, as is the case with irinotecan and floxuridine. Considering
the significant differences in solubility properties of irinotecan
and floxuridine, we contemplated establishing formulation
conditions that would differentially control the entrapment
and retention of these two drugs. As a very water-soluble
compound (>400 mg/ml), floxuridine can be readily entrapped
passively during liposome production and its release from
liposomes will be predominately controlled by lipid perme-
ability properties. In comparison, irinotecan can be actively
entrapped inside liposomes with high efficiency using trans-
membrane pH gradients [30]. However, the use of pH gradients
can be problematic due to the instability of phospholipids
exposed to the acidic liposome interior which can lead to altered
drug retention properties [31]. We therefore examined the use of
encapsulated transition metals to actively load irinotecan
without the use of pH gradients.
The rationale for utilizing encapsulated transition metals to
actively load and retain irinotecan was based on the more than
40 years of evidence documenting interactions between
transition metals and drugs [19]. We observed that only copper
and zinc were able to promote the efficient encapsulation of
irinotecan when high concentrations of liposome encapsulated
unbuffered metal sulfates were utilized. The other metal sulfates
tested (Ni, Mn, Co) provided little or no encapsulation under the
conditions utilized even though MnSO4 was previously
reported to promote the encapsulation of doxorubicin into
liposomes [32]. The pH of these unbuffered metal solutions
ranged from a low of 3.3 for MnSO4 to a high of 5.5 for CoSO4.
Based on this information and the loading curves, there
appeared to be no correlation between the pH of the
encapsulated salt solution and the extent of drug encapsulation.
The lack of irinotecan uptake in the presence of MnSO4
observed here contrasts the results obtained previously with
another weak base camptothecin, topotecan, where liposomes
containing this metal and the ionophore A23187 actively
accumulated the drug [33]. This difference is related to the fact
that in the presence of the ionophore, a transmembrane pH
gradient (inside acidic) is generated which drives drug uptake.
The fact that irinotecan does not load into the MnSO4 without
an ionophore indicates that the encapsulation observed here is
not due to a pH gradient, but rather is related to selectiveinteractions between irinotecan and the transition metals copper
and zinc. The strength of the irinotecan interaction, correlates
with the stability constants commonly observed with metal
complexes [34]. Specific interactions between copper and the
anthracyclines have been previously reported [35,36].
We were also able to achieve efficient loading using
liposomes containing copper gluconate buffered to physiologi-
cal pH with TEA, thereby alleviating potential difficulties with
lipid degradation at acidic pH. When the influence of internal
and external pH on the encapsulation of irinotecan was
investigated, significantly lower irinotecan encapsulation was
observed with decreasing pH. This may be the result of a
decreased irinotecan permeability at lower pH due to a larger
fraction of protonated amine, decreased interactions between
irinotecan and copper gluconate/TEA or a combination of both.
The mechanism responsible for this decrease has not been fully
elucidated at this time. When the starting drug to lipid ratio was
increased to 0.3:1, irinotecan encapsulation reached a max-
imum drug to lipid ratio of 0.18:1. This saturation effect
suggests a stoichiometric relationship between irinotecan and
copper gluconate/TEA. Further investigations are underway to
fully characterize the nature of the interaction between
irinotecan and copper gluconate/TEA inside liposomes. It is
important to note that preliminary evidence for this buffer
system indicates that TEA plays a major role in mediating the
encapsulation and retention of irinotecan in contrast to the case
of unbuffered copper sulfate where evidence for a direct
irinotecan–copper interaction was obtained [37]. The copper
gluconate/TEA irinotecan loading process described here
provided an encapsulation system that was more amenable to
pharmaceutical applications and was therefore utilized in an
iterative optimization process to coordinate the release of
irinotecan and floxuridine in vivo. This copper based formula-
tion of irinotecan and floxuridine has been evaluated in dog
toxicological studies and no evidence of copper toxicity was
detected.
When floxuridine and irinotecan encapsulated in liposomes
were administered i.v. to mice, surprising trends were observed
in drug pharmacokinetics as a function of lipid composition.
Historically, liposomes composed of saturated phospholipids
and high cholesterol content (>33 mol%) have provided
maximum drug retention in vivo for a wide range of drugs
[38,39]. More recently, we demonstrated that for some drugs,
low cholesterol-containing gel phase liposomes can reduce in
vivo drug release compared to cholesterol-enriched systems
[23]. In the studies here we observed a rather striking
dependence of irinotecan and floxuridine leakage from
DSPC-based liposomes in that the relationship between drug
release and cholesterol content in the liposome was diame-
trically opposed for the two drugs. Whereas cholesterol-free
DSPC/DSPG liposomes displayed optimal floxuridine reten-
tion, irinotecan was rapidly released from these systems. By
titrating the cholesterol content in DSPC/DSPG liposomes
containing floxuridine/irinotecan at a 1:1 ratio and assessing
the plasma drug release properties after i.v. injection, we were
able to identify that liposomes composed of DSPC/DSPG/
Chol at a 70:20:10 molar ratio were able to coordinate the
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drug/drug ratio was maintained at approximately 1:1 for up to
24 h. The fact that the circulating drug to lipid ratios for both
irinotecan and floxuridine decrease at the same rate over time
indicates that both drugs are bioavailable and are being
exposed systemically at the 1:1 ratio.
When liposomes were passively encapsulated with floxur-
idine and subsequently loaded with irinotecan, the temperature
of loading had a dramatic impact on the drug content of the final
formulation. In the cholesterol-free and low cholesterol
formulations, irinotecan encapsulation was almost immediate
at 60 °C. Unfortunately, this temperature resulted in over 90%
floxuridine leakage within 2 min. This rapid leakage is likely
the result of heating the liposomes above their transition
temperature of 55 °C. Since these liposomes contain very little
cholesterol, bilayer fluidity at these temperatures prevents
adequate retention of floxuridine. Complete retention of
floxuridine could be achieved at 40 °C, however, the encap-
sulation of irinotecan at this temperature was observed to be
very poor. Consequently, a temperature of 50 °C was identified
at which irinotecan could be encapsulated with high efficiency
with manageable loss of floxuridine such that the target 1:1 drug
ratio could be achieved. Although this was achievable in
formulation batches less than 10 mL, it was not possible to
achieve the desired accuracy and reproducibility in larger
volumes.
In order to resolve this problem, an alternative loading
scheme was developed based on the observed leakage of
floxuridine at 50 °C. The high permeability of floxuridine near
the phase transition temperature of the formulation allowed for
the passive loading of floxuridine during irinotecan encapsula-
tion. Analysis of the drug loading curves in Fig. 8 for the two
drugs revealed very similar kinetics. This is somewhat
surprising since the mechanisms driving the encapsulation of
floxuridine and irinotecan are quite different and the two drugs
display very different drug release dependence on cholesterol
content. This method, however, has allowed us to control the
encapsulated drug/drug molar ratio over a wide range of time.
This unique dual loading method has the advantage over
sequential loading in that the liposomes are prepared and
extruded in the absence of chemotherapeutics and the final
drug/drug ratio in the formulation can be tightly controlled.
This report describes one of the first attempts to co-formulate
drug combinations in a manner that coordinates the pharmaco-
kinetics of the different drugs after i.v. administration. By
combining copper gluconate/TEA-based drug encapsulation and
low-cholesterol containing gel phase liposomes, we were able to
encapsulate and maintain irinotecan and floxuridine at a fixed,
synergistic molar ratio of 1:1. We believe that maintaining this
ratio will be critical to maximizing the therapeutic activity of this
drug combination, based on results in tumor models [9,29]. As
more cancer therapies utilize a greater number of agents, it will
become increasingly important to avoid antagonistic drug
interactions in order to maximize therapeutic activity. Since
the pharmacokinetics of the individual drugs in conventional
combination treatments cannot be controlled, formulating
multiple drugs into delivery vehicles that can coordinate theirpharmacokinetics is a viable approach to optimize the thera-
peutic activity of multiple agent combinations.
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